Open AccessThe potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
Author(s) -
William G. Herrington,
David Preiss,
Richard Haynes,
Maximilian von Eynatten,
Natalie Staplin,
Sibylle J. Hauske,
Jyothis T. George,
Jennifer B. Green,
Martin Landray,
Colin Baigent,
Christoph Wanner
Publication year - 2019
Publication title -
clinical kidney journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.033
H-Index - 40
eISSN - 2048-8513
pISSN - 2048-8505
DOI - 10.1093/ckj/sfz009
Subject(s) - medicine , empa , kidney disease , empagliflozin , transporter , diabetes mellitus , kidney , endocrinology , sodium , disease , urology , type 2 diabetes , biochemistry , gene , mineralogy , organic chemistry , chemistry , electron microprobe
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom